Daiichi Sankyo's edoxaban holds its own in clinical testing


Daiichi Sankyo's (DSKYF) edoxaban again proves comparable to warfarin in late stage clinicals.

In a study of patients with A-fib, 1.5% of those given warfarin experienced a stroke versus 1.18% of those given the highest dose of edoxaban and 1.6% of those given the lower dose.

Bleeding was less common in those given edoxaban.

There were also fewer deaths among edoxaban patients.

Despite the data, some say there isn't enough evidence to warrant wholesale adoption: "The absolute risk reduction is small," a professor at McMaster University’s Department of Medicine tells Bloomberg.

Competitors: PFE and BMY's Eliquis and JNJ's Xarelto.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs